Fig. 6
From: Exploring the role of RALYL in Alzheimer’s disease reserve by network-based approaches
RALYL expression dynamic features in AD. a, b Expression characteristics of RALYL in AD disease progression (incipient AD, moderate AD, and severe AD; normal aging as a control group) in AD microarray dataset GSE1297 and GSE28146. RALYL decreases during the development of moderate AD to severe AD in GSE1297 (multiple one-way ANOVA, adjusted p = 0.0027) and GSE28146 (multiple one-way ANOVA, adjusted p = 0.032). c RALYL expression levels between NCI, MCI, and AD dementia in ROSMAP RNA-seq dataset (multiple one-way ANOVA, adjusted p = 0.022). d Subjects with reserve have high RALYL expression. Left: MMSE score decline from the first AD diagnoses to last validation from subjects with low RALYL expression (fourth quartile of expression levels). Right: MMSE score decline from the first AD diagnoses to last validation from subjects with high RALYL expression (first quartile of expression levels) (multiple t test, adjusted p = 0.019). e Specific to AD reserve, subjects with reserve have high expression of RALYL than loss reserve subjects (multiple t test, adjusted p = 0.046)